<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04955886</url>
  </required_header>
  <id_info>
    <org_study_id>HMPL-012-SPRING-HNC104</org_study_id>
    <nct_id>NCT04955886</nct_id>
  </id_info>
  <brief_title>Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma</brief_title>
  <official_title>Efficacy and Safety of Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma : a Prospective, Single Arm and Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, single-arm,mutil-center study to assess the efficacy and safety of Surufatinib&#xD;
      combined with Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study adopt Simon's two-stage Optimal designs method based on the primary endpoint of&#xD;
      objective response rates. 4 patients were planned for the first stage. If one or more&#xD;
      responses were observed, an additional 8 patients were to be accrued for a total of 12&#xD;
      patients. If 4 or more of the 12 patients achieved an objective response, then this study was&#xD;
      designated worthy of additional investigation.Considering a 10% abscission rate, a total of&#xD;
      14 patients were included.&#xD;
&#xD;
      Surufatinib（250mg) will be orally administered within 1 hour after breakfast once a day (QD)&#xD;
      , Toripalimab was administered intravenously at a fixed dose of 240 mg, and the infusion time&#xD;
      was 60 ± 5 min, once every 21 days. The cumulative longest medication period is 2 years.&#xD;
      Until disease progression, death, intolerable toxicity or other protocol specified&#xD;
      end-of-treatment criteria is met .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>CR + PR rate according to the RECIST version 1.1 guidelines.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>To assess the efficacy of Surufatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma. patients by assessment of progression free survival (PFS) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival time</measure>
    <time_frame>up to 36 months</time_frame>
    <description>OS was calculated from the date of pharmacy to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the anti-tumor activity:DCR</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Disease control rate (DCR):CR + PR + SD rate according to the RECIST version 1.1 guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of relief (DOR)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The length of time that a tumor continues to respond to treatment without the cancer growing or spreading.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Recurrent or Metastatic Nasopharyngeal Carcinoma.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma were given Surufatinib Combined With Toripalimab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surufatinib(HMPL-012)</intervention_name>
    <description>Surufatinib(250mg) will be orally administered within 1 hour after breakfast once a day (QD) , Toripalimab was administered intravenously at a fixed dose of 240 mg, and the infusion time was 60 ± 5 min, once every 21 days. The cumulative longest medication period is 2 years. Until disease progression, death, intolerable toxicity or other protocol specified end-of-treatment criteria is met .</description>
    <arm_group_label>Recurrent or Metastatic Nasopharyngeal Carcinoma.</arm_group_label>
    <other_name>Toripalimab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of written Informed Consent Form (ICF) prior to any study specific&#xD;
             procedures;&#xD;
&#xD;
          2. Male and Female aged between 18 and 75 years are eligible;&#xD;
&#xD;
          3. Histologically or cytologically confirmed that Recurrent or Metastatic Nasopharyngeal&#xD;
             Carcinoma.&#xD;
&#xD;
          4. Patients must have received at least one standard platinum-based systemic chemotherapy&#xD;
             regimen for the treatment of recurrent or metastatic NPC;Or the insensitivity or&#xD;
             intolerance to platinum when the patient has previously received radical therapy;&#xD;
&#xD;
          5. Not suitable for local treatment (no radiotherapy or surgery);&#xD;
&#xD;
          6. Presence of at least one measurable target lesion for further evaluation according to&#xD;
             RECIST criteria;&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status 0-2;&#xD;
&#xD;
          8. Screening laboratory values must meet the following criteria (within past 14 days):&#xD;
&#xD;
               -  neutrophils ≥1.5×109/L ;&#xD;
&#xD;
               -  platelets ≥100×109/L；&#xD;
&#xD;
               -  hemoglobin ≥ 10 g/dL;&#xD;
&#xD;
               -  total bilirubin ≤ 1.5 x upper limit of normal (ULN); aspartic transaminase (AST)&#xD;
                  and alanine transaminase (ALT) ≤ 2.5 x ULN without, and ≤ 5 x ULN with hepatic&#xD;
                  metastasis; serum creatinine ≤1.5╳ULN;&#xD;
&#xD;
          9. Ability to follow the program;&#xD;
&#xD;
         10. Toxic side effects of any previous chemotherapy have returned to less than or equal to&#xD;
             NCI CTCAE1 level or baseline;&#xD;
&#xD;
         11. Predicted survival &gt;3 months;&#xD;
&#xD;
         12. Males or female of childbearing potential must: agree to use using a reliable form of&#xD;
             contraception (eg, oral contraceptives, intrauterine device, control sex desire,&#xD;
             double barrier method of condom and spermicidal) during the treatment period and for&#xD;
             at least 6 months after the last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The pathological type was neuroendocrine or small cell carcinoma;&#xD;
&#xD;
          2. Evidence with active CNS disease or previous brain metastases;&#xD;
&#xD;
          3. Prior received anti-tumor monoclonal antibodies or other investigational drugs within&#xD;
             the first 4 weeks of enrollment;Previous treatment with other anti-PD-1 antibodies or&#xD;
             other treatments targeting PD-1 / PD-L1.&#xD;
&#xD;
          4. Prior treatment with Surufatinib,or other antiangiogenic drugs were used ;&#xD;
&#xD;
          5. Patients were on immunosuppressive or systemic hormone therapy (doses greater than&#xD;
             10mg/day prednisone or other equivalent hormone) for immunosuppressive purposes and&#xD;
             were still on it within 2 weeks prior to enrolment;&#xD;
&#xD;
          6. The patient has any active autoimmune disease or a history of autoimmune disease;&#xD;
&#xD;
          7. Have clinical cardiac symptoms or diseases that are not well controlled;&#xD;
&#xD;
          8. Patients with congenital or acquired immune deficiency;&#xD;
&#xD;
          9. Chemotherapy, targeted therapy and radiotherapy were received within 2 weeks before&#xD;
             enrollment;&#xD;
&#xD;
         10. Patients who had a history of gastrointestinal perforation or had undergone major&#xD;
             surgery 4 weeks before enrollment;&#xD;
&#xD;
         11. During the first 6 months of enrollment, there were arterial/venous thrombosis events,&#xD;
             such as non-cardiovascular and cerebrovascular (including temporary ischemic attack),&#xD;
             deep vein thrombosis (except for venous thrombosis caused by intravenous&#xD;
             catheterization during pre-chemotherapy, which was determined by the investigators to&#xD;
             be cured), and pulmonary embolism;&#xD;
&#xD;
         12. Patients with abnormal coagulation function (International normalized ratio (INR) &gt;1.5&#xD;
             or partially activated prothrombin time (APTT) &gt;1.5×ULN), bleeding tendency (such as&#xD;
             active ulcer lesions in the stomach, occlusive blood in the stool (++), melenia and/or&#xD;
             hematemesis and hemoptysis within 3 months) or lesions close to large vessels.The&#xD;
             lesions involved in the skin or mucosal cavity are at risk of rupture;&#xD;
&#xD;
         13. Hypertension that cannot be controlled by medication;&#xD;
&#xD;
         14. Routine urine indicated more than 2+ urine protein or 24 hours urine protein &gt;150mg/L;&#xD;
&#xD;
         15. Calibration of QT interval &gt; 470MSEC;If the patient has an extended QT interval, but&#xD;
             the investigator's study evaluates the prolonged period as due to a pacemaker (and no&#xD;
             other cardiac abnormality), it is up to the investigator to determine whether the&#xD;
             patient is eligible for the study;&#xD;
&#xD;
         16. Had other malignant tumors in the past 5 years (except for basal cell carcinoma or&#xD;
             squamous cell carcinoma, cervical carcinoma in situ that have been effectively&#xD;
             controlled);&#xD;
&#xD;
         17. Known to be allergic to drug ingredients;&#xD;
&#xD;
         18. Patients at risk of massive bleeding in the nasopharynx or deep ulcers in the&#xD;
             nasopharynx.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sufang Qiu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fujian Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sufang Qiu, MD</last_name>
    <phone>13609589163</phone>
    <email>sfqiu@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Affiliated Cancer Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangdong</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Fei Han, MD</last_name>
      <phone>13822113698</phone>
      <email>hanfei@sysucc.org.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Guopei Zhu, MD</last_name>
      <phone>13774338182</phone>
      <email>antica@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 5, 2021</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2021</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

